PAASHEUVELWEG 25A, AMSTERDAM, P7
Investor Presentation
Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
Financial Results, Press Release
Announces Pricing of Upsized $225 Million Public Offering
Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease
Shareholders Approve Amendment to 2014 Share Incentive Plan
Earnings Release
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities